EGFR and posterior cortical atrophy: Synthetic lethality between RPS6KA2 and erlotinib (EGFR inhibitor) is shown in PCa, supporting extensive crosstalk between MAPK and Akt pathways in PCa, and illustrates the clinical potential for combinatory treatments affecting these pathways [50]; these pathways are also affected by the APIM-peptide.